AIDS and Behavior

, Volume 16, Issue 8, pp 2171–2180 | Cite as

OPRM1 and Diagnosis-Related Posttraumatic Stress Disorder in Binge-Drinking Patients Living with HIV

  • Nicole R. Nugent
  • Michelle A. Lally
  • Larry Brown
  • Valerie S. Knopik
  • John E. McGeary
Original Paper

Abstract

Posttraumatic stress disorder (PTSD) has been linked to numerous negative outcomes in persons living with HIV (PLH) and there is evidence that PTSD symptoms may play a role in maintaining alcohol use problems. The opioid receptor mu-1 (OPRM1) gene may play a role in both PTSD and alcohol use. We examined the association between PTSD and drinking motives as well as variation in the OPRM1 as a predictor of both PTSD and drinking motives in a sample of 201 PLH reporting recent binge drinking. Self-reported PTSD symptom severity was significantly associated with drinking motives for coping, enhancement, and socialization. OPRM1 variation was associated with decreased PTSD symptom severity as well as enhancement motives for drinking.

Keywords

HIV Binge drinking PTSD OPRM1 Gene 

Notes

Acknowledgments

This research was funded by a 2008 developmental grant from the Lifespan/Tufts/Brown Center for AIDS Research. The project described was supported by Grant Number P30AI042853 from the National Institute Of Allergy And Infectious Diseases. Content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Allergy And Infectious Diseases or the National Institute of Health. Dr. Nugent is supported by US-NIMH K01 MH087240. Work was supported by 1S10RR023457 and Shared equipment grants (ShEEP) from the Medical Research Service of the Department of Veteran Affairs, awarded to J. E. McGeary. This material is the result of work supported with resources and the use of facilities at the Providence VA Medical Center.

References

  1. 1.
    Kelly B, Raphael B, Judd F, Perdices M, Kernutt G, Burnett P, et al. Posttraumatic stress disorder in response to HIV infection. Gen Hosp Psychiatry. 1998;20(6):345–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Leserman J, Whetten K, Lowe K, Strangl D, Schwartz M, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the South. Psychosom Med. 2005;67:500–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Safren SA, Gershuny BS, Hendriksen E. Symptoms of posttraumatic stress and death anxiety in persons with HIV and medication adherence difficulties. AIDS Patient Care STDS. 2003;17(12):657–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Katz S, Nevid JS. Risk factors associated with posttraumatic stress disorder symptomatology in HIV-infected women. AIDS Patient Care STDS. 2005;19(2):110–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Vranceanu AM, Safren SA, Lu M, Coady WM, Skolnik PR, Rogers WH, et al. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS. 2008;22(4):313–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin L, Kagee A. Lifetime and HIV-related PTSD among persons recently diagnosed with HIV. AIDS Behav. 2011;15(1):125–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Martinez A, Israelski D, Walker C, Koopman C. Posttraumatic stress disorder in women attending human immunodeficiency virus outpatient clinics. AIDS Patient Care STDS. 2002;16(6):283–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Boarts J, Sledjeski E, Bogart L, Delahanty D. The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav. 2006;10(3):253–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen MA, Alfonso CA, Hoffman RG, Milau V, Carrera G. The impact of PTSD on treatment adherence in persons with HIV infection. Gen Hosp Psychiatry. 2001;23(5):294–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Delahanty DL, Bogart LM, Figler JL. Posttraumatic stress disorder symptoms, salivary cortisol, medication adherence, and CD4 levels in HIV-positive individuals. AIDS Care. 2004;16:247–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Olley BO, Bolajoko AJ. Psychosocial determinants of HIV-related quality of life among HIV-positive military in Nigeria. Int J STD AIDS. 2008;19(2):94–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 2006;194(9):690–6. doi: 10.1097/01.nmd.0000235794.12794.8a.PubMedCrossRefGoogle Scholar
  13. 13.
    Hien DA, Jiang H, Campbell ANC, Hu M-C, Miele GM, Cohen LR, et al. Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA’s clinical trials network. Am J Psychiatry. 2010;167(1):95–101.PubMedCrossRefGoogle Scholar
  14. 14.
    Grayson CE, Nolen-Hoeksema S. Motives to drink as mediators between childhood sexual assault and alcohol problems in adult women. J Trauma Stress. 2005;18(2):137–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Ullman SE, Filipas HH, Townsend SM, Starzynski LL. Trauma exposure, posttraumatic stress disorder and problem drinking in sexual assault survivors. J Stud Alcohol. 2005;66:610–9.PubMedGoogle Scholar
  16. 16.
    Miranda R, Meyerson LA, Long PJ, Marx BP, Simpson SM. Sexual assault and alcohol use: exploring the self-medication hypothesis. Violence Vict. 2002;17:205–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Simpson TL. Childhood sexual abuse, PTS, and the functional roles of alcohol use among women drinkers. Subst Use Misuse. 2003;38(2):249–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Chander G, Himelhoch S, Moore R. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66:769–89.PubMedCrossRefGoogle Scholar
  19. 19.
    Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Syndr. 2006;42(3):298–306. doi: 10.1097/01.qai.0000219773.82055.aa.PubMedCrossRefGoogle Scholar
  20. 20.
    Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav. 2003;7(2):101–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Merenlender-Wagner A, Dikshtein Y, Yadid G. The endorphin role in stress-related psychiatric disorders. Curr Drug Targets. 2009;10:1096–108.PubMedCrossRefGoogle Scholar
  22. 22.
    Saxe G, Geary M, Bedard K, Bosquet M, Miller A, Koenen K, et al. Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann NY Acad Sci. 2006;1071:41–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Saxe G, Stoddard F, Courtney D, Cunningham K, Chawla N, Sheridan R, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry. 2001;40(8):915–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010;362(2):110–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Bryant RA, Creamer M, O’Donnell M, Silove D, McFarlane AC. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009;65(5):438–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Morgan CA, Krystal JH, Southwick SM. Toward early pharmacological posttraumatic stress intervention. Biol Psychiatry. 2003;53(9):834–43.PubMedCrossRefGoogle Scholar
  27. 27.
    McGaugh JL, Introini-Collison IB, Nagahara AH. Memory-enhancing effects of post-training naloxone: involvement of fl-noradrenergic influences in the amygdaloid complex. Brain Res. 1988;446(1):37–49.PubMedCrossRefGoogle Scholar
  28. 28.
    Kreek MJ, Schlussman SD, Reed B, Zhang Y, Nielsen DA, Levran O, et al. Bidirectional translational research: progress in understanding addictive diseases. Neuropharmacology. 2009;56:32–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human Mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95(16):9608–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Wand G, McCaul M, Gotjen D, Reynolds J, Lee S. Confirmation that offspring from families with alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol Clin Exp Res. 2001;25(8):1134–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet. 2003;118B(1):60–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Yehuda R, Golier J. Is there a rationale for cortisol-based treatments for PTSD? Expert Rev Neurother. 2009;9(8):1113–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Pitman RK, Delahanty DL. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr. 2005;10(2):99–106.PubMedGoogle Scholar
  34. 34.
    Delahanty DL, Nugent NR. Predicting PTSD prospectively based on prior trauma history, trauma severity, and immediate biologic responses. Ann NY Acad Sci. 2006;1071:27–40.PubMedCrossRefGoogle Scholar
  35. 35.
    Amstadter AB, Nugent NR, Koenen KC. Genetics of PTSD: fear conditioning as a model for future research. Psychiatric Ann. 2009;39(6):358–67.CrossRefGoogle Scholar
  36. 36.
    Pitman RK, van der Kolk BA, Orr SP, Greenberg MS. Naloxone-reversible analgesic response to combat-related stimuli in posttraumatic stress disorder. a pilot study. Arch Gen Psychiatry. 1990;47(6):541–4.PubMedCrossRefGoogle Scholar
  37. 37.
    van der Kolk BA, Greenberg MS, Orr SP, Pitman RK. Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacol Bull. 1989;25(3):417–21.PubMedGoogle Scholar
  38. 38.
    Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993;30(4):255–63.PubMedGoogle Scholar
  39. 39.
    Liberzon I, Taylor SF, Phan KL, Britton JC, Fig LM, Bueller JA, et al. Altered central mu-Opioid receptor binding after psychological trauma. Biol Psychiatry. 2007;61(9):1030–8.PubMedCrossRefGoogle Scholar
  40. 40.
    van den Wildenberg E, Wiers RW, Dessers J, Janssen RGJH, Lambrichs EH, Smeets HJM, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res. 2007;31(1):1–10.PubMedCrossRefGoogle Scholar
  41. 41.
    McGeary J, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288–96.PubMedCrossRefGoogle Scholar
  42. 42.
    Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789–95.PubMedCrossRefGoogle Scholar
  43. 43.
    Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069–77.PubMedCrossRefGoogle Scholar
  44. 44.
    Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of (micro)-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (combine) Study. Arch Gen Psychiatry. 2008;65(2):135–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Filbey F, Ray L, Smolen A, Claus E, Audette A, Hutchinson KE. Differential neural response to alcohol proming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res. 2008;32(7):1113–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2010;16(18):809–17.PubMedGoogle Scholar
  47. 47.
    Wiers R, Rinck M, Dictus M, van den Wildenberg E. Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. Genes Brain Behav. 2009;8(1):101–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Ray LA. Stress-induced and cue-induced craving for alcohol in heavy drinkers: preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. Alcohol Clin Exp Res. 2010;35(1):166–74.PubMedCrossRefGoogle Scholar
  49. 49.
    Max M, Wu T, Atlas S, Edwards R, Haythornthwaite J, Bollettino A, et al. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain. 2006;2(1):14.PubMedCrossRefGoogle Scholar
  50. 50.
    Matsunaga M, Isowa T, Murakami H, Kasugai K, Yoneda M, Kaneko H, et al. Association of polymorphism in the human (mu)-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. Brain Behav Immu. 2009;23(7):931–5.CrossRefGoogle Scholar
  51. 51.
    Norman SB, Stein MB, Davidson JRT. Profiling posttraumatic functional impairment. J Nerv Ment Dis. 2007;195(1):48–53. doi: 10.1097/01.nmd.0000252135.25114.02.PubMedCrossRefGoogle Scholar
  52. 52.
    Marshall RD, Olfson M, Hellman F, Blanco C, Guardino M, Struening EL. Comorbidity, impairment, and suicidality in subthreshold PTSD. Am J Psychiatry. 2001;158:1467–73.PubMedCrossRefGoogle Scholar
  53. 53.
    Grubaugh AL, Magruder KM, Waldrop AE, Elhai JD, Knapp RG, Frueh BC. Subthreshold PTSD in primary care: prevalence, psychiatric disorders, healthcare use, and functional status. J Nerv Ment Dis. 2005;193(10):658–64.PubMedCrossRefGoogle Scholar
  54. 54.
    Breslau N, Lucia VC, Davis GC. Partial PTSD versus full PTSD: an empirical examination of associated impairment. Psychol Med. 2004;34(07):1205–14.PubMedCrossRefGoogle Scholar
  55. 55.
    Corapioglu A, Tural U, et al. Subthreshold post traumatic stress disorder in the survivors of Marmara earthquake. Primary Care Psychiatry. 2004;9(4):137–44.CrossRefGoogle Scholar
  56. 56.
    Cukor J, Wyka K, Jayasinghe N, Difede J. The nature and course of subthreshold PTSD. J Anxiety Disord. 2010;24(8):918–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Galai N, Strathdee SA, Vlahov D, Bareta J, Macalino G, Celentano DD. ACASI versus interview administered questionnaires for sensitive risk behaviors: Results of a cross-over randomized trial among injection drug users. International Conference on AIDS. 2004;15:11–6.Google Scholar
  58. 58.
    Waruru AK, Nduati R, Tylleskar T. Audio computer-assisted self-interviewing (ACASI) may avert socially desirable responses about infant feeding in the context of HIV. BMC Med Inform Decis Mak. 2005;5(24):1–7.Google Scholar
  59. 59.
    Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB. The reach (reaching for excellence in adolescent care and health) project: study design, methods, and population profile. J Adolesc Health. 2001;29(3):8–18.PubMedCrossRefGoogle Scholar
  60. 60.
    Saunders JB, Aasland O, Babor T, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791–804.PubMedCrossRefGoogle Scholar
  61. 61.
    Babor TF, de la Fuente JR, Saunders J, Grant M, editors. AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care, revision, WHO document No. WHO/PSA/92.4. Geneva: World Health Organization; 1992.Google Scholar
  62. 62.
    Weiss D, Marmar CR, editors. The impact of event scale—revised. New York: Guilford; 1997.Google Scholar
  63. 63.
    Cooper ML, Russell M, Skinner JB, Windle M. Development and validation of a three-dimensional measure of drinking motives. Psychol Assess. 1992;4:123–32.CrossRefGoogle Scholar
  64. 64.
    Muthen LK, Muthen BO. Mplus Version 3.11. Los Angeles: Muthen & Muthen; 2004.Google Scholar
  65. 65.
    Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R. DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet. 1997;27(3):251–7.Google Scholar
  66. 66.
    Lench N, Stainer P, Williamson R. Simple noninvasive method to obtain DNA for gene analysis. Lancet. 1988;1(8599):1356–8.Google Scholar
  67. 67.
    Meulenbelt I, Droog S, Trommelen GJ, et al. High-yield noninvasive human genomic DNA isolation method for genetic studies in geographically dispersed families and populations. Am J Hum Genet. 1995;57:1252–4.Google Scholar
  68. 68.
    Spitz E, Moutier R, Reed T, et al. Comparative diagnoses of twin zygosity by SSLP variant analysis, questionnaires, and dermatoglyphic analysis. Behav Genet. 1996;26:55–63.Google Scholar
  69. 69.
    O’Cleirigh C, Ironson G, Smits JAJ. Does distress tolerance moderate the impact of major life events on psychosocial variables and behaviors important in the management of HIV? Behav Ther. 2007;38(3):314–23.PubMedCrossRefGoogle Scholar
  70. 70.
    Ironson G, O’Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, et al. Psychosocial factors predict CD4 and viral load change in men and women with HIV in the era of HAART. Psychosom Med. 2005;67:1013–21.PubMedCrossRefGoogle Scholar
  71. 71.
    Creamer M, Bell R, Failla S. Psychometric properties of the impact of event scale-revised. Behav Res Ther. 2003;41:1489–96.PubMedCrossRefGoogle Scholar
  72. 72.
    Asukai N, Kato H, Kawamura N, Kim YH, Yamamoto K, Kishimoto J, et al. Reliability and validity of the Japanese-language version of the impact of event scale-revised (Ies-R-J): four studies of different traumatic events. J Nerv Ment Dis. 2002;190(3):175–82.PubMedCrossRefGoogle Scholar
  73. 73.
    Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the (mu)-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3):262–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Dixon LJ, Leen-Feldner EW, Ham LS, Feldner MT, Lewis SF. Alcohol use motives among traumatic event-exposed, treatment-seeking adolescents: associations with posttraumatic stress. Addict Behav. 2009;34(12):1065–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Gu C, Li P, Hu B, Ouyang X, Fu J, Gao J, et al. Chronic morphine selectively impairs cued fear extinction in rats: implications for anxiety disorders associated with opiate use. Neuropsychopharmacology. 2007;33(3):666–73.PubMedCrossRefGoogle Scholar
  76. 76.
    Ho W-Z, Guo C-J, Yuan C-S, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther. 2003;307(3):1158–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology. 2003;309(1):99–107.PubMedCrossRefGoogle Scholar
  78. 78.
    Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11(5):354–65.PubMedCrossRefGoogle Scholar
  79. 79.
    Delahanty DL, Nugent NR, Christopher NC, Walsh M. Initial urinary epinephrine and cortisol levels predict acute PTSD symptoms in child trauma victims. Psychoneuroendocrinology. 2005;30(2):121–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Delahanty DL, Raimonde AJ, Spoonster E. Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accidents. Biol Psychiatry. 2000;48(9):940–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Amstadter A, Nugent NR, Yang BZ, Saxe G, Smoller J, Moorjan P, Haddad S, Basu A, Siburian R, Fagerness J, Koenen K. Corticotropin Releasing Hormone gene (CRHR1) and PTSD in pediatric injury patients. Special Issue of Disease Markers: Molecular Biology of PTSD. 2011;30(2–3):89–99.Google Scholar
  82. 82.
    Hernandez-Avila C, Covault J, Wand G, Zhang H, Gelernter J, Kranzler H. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics. 2007;17(12):1031–8.PubMedCrossRefGoogle Scholar
  83. 83.
    van der Zwaluw CS, van den Wildenberg E, Wiers RW, Franke B, Buitelaar J, Scholte RHJ, et al. Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. Pharmacogenomics. 2007;8(10):1427–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2011

Authors and Affiliations

  • Nicole R. Nugent
    • 1
    • 2
    • 3
  • Michelle A. Lally
    • 4
    • 5
  • Larry Brown
    • 2
    • 3
  • Valerie S. Knopik
    • 1
    • 2
    • 3
  • John E. McGeary
    • 1
    • 3
    • 6
  1. 1.Division of Behavioral Genetics, Department of PsychiatryRhode Island HospitalProvidenceUSA
  2. 2.Bradley/Hasbro Research CenterRhode Island HospitalProvidenceUSA
  3. 3.Department of Psychiatry and Human BehaviorAlpert Brown Medical SchoolProvidenceUSA
  4. 4.Miriam HospitalProvidenceUSA
  5. 5.Department of MedicineAlpert Brown Medical SchoolProvidenceUSA
  6. 6.Department of Veterans AffairsProvidence VA Medical Center, Research ServiceProvidenceUSA

Personalised recommendations